C.R. Bard, Inc. (NYSE:BCR) insider John P. Groetelaars sold 23,687 shares of the business’s stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the completion of the sale, the insider now directly owns 31,445 shares in the company, valued at approximately $10,022,464.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of C.R. Bard, Inc. (BCR) traded up 0.36% during trading on Friday, hitting $320.28. 149,945 shares of the stock traded hands. C.R. Bard, Inc. has a 12 month low of $203.63 and a 12 month high of $323.27. The company has a 50 day moving average price of $318.89 and a 200 day moving average price of $282.81. The firm has a market cap of $23.28 billion, a price-to-earnings ratio of 42.05 and a beta of 0.59.
C.R. Bard (NYSE:BCR) last issued its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.84 by $0.08. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. The company had revenue of $979.70 million during the quarter, compared to analysts’ expectations of $976.53 million. During the same period last year, the company posted $2.54 EPS. C.R. Bard’s revenue was up 5.2% on a year-over-year basis. Analysts anticipate that C.R. Bard, Inc. will post $11.84 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Friday, August 4th. Investors of record on Monday, July 24th were given a dividend of $0.26 per share. The ex-dividend date was Thursday, July 20th. This represents a $1.04 dividend on an annualized basis and a yield of 0.33%. C.R. Bard’s dividend payout ratio (DPR) is currently 13.67%.
COPYRIGHT VIOLATION WARNING: “C.R. Bard, Inc. (NYSE:BCR) Insider John P. Groetelaars Sells 23,687 Shares” was posted by Ticker Report and is owned by of Ticker Report. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.tickerreport.com/banking-finance/2802238/c-r-bard-inc-nysebcr-insider-john-p-groetelaars-sells-23687-shares.html.
Several analysts recently weighed in on the stock. BidaskClub cut shares of C.R. Bard from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Jefferies Group LLC reissued a “hold” rating on shares of C.R. Bard in a research note on Thursday, August 3rd. Zacks Investment Research cut shares of C.R. Bard from a “buy” rating to a “hold” rating in a research note on Tuesday, August 1st. Finally, BMO Capital Markets reissued a “hold” rating and issued a $317.00 price objective on shares of C.R. Bard in a research note on Tuesday, July 11th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, one has given a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $285.67.
A number of hedge funds and other institutional investors have recently modified their holdings of BCR. Macquarie Group Ltd. boosted its position in shares of C.R. Bard by 61.1% in the fourth quarter. Macquarie Group Ltd. now owns 5,800 shares of the medical instruments supplier’s stock valued at $1,303,000 after buying an additional 2,200 shares during the period. Creative Planning boosted its position in shares of C.R. Bard by 0.7% in the first quarter. Creative Planning now owns 4,298 shares of the medical instruments supplier’s stock valued at $1,068,000 after buying an additional 29 shares during the period. Gulf International Bank UK Ltd boosted its position in shares of C.R. Bard by 1.0% in the first quarter. Gulf International Bank UK Ltd now owns 23,124 shares of the medical instruments supplier’s stock valued at $5,747,000 after buying an additional 220 shares during the period. Pennsylvania Trust Co boosted its position in shares of C.R. Bard by 2.9% in the first quarter. Pennsylvania Trust Co now owns 1,240 shares of the medical instruments supplier’s stock valued at $308,000 after buying an additional 35 shares during the period. Finally, Legacy Private Trust Co. boosted its position in shares of C.R. Bard by 28.4% in the first quarter. Legacy Private Trust Co. now owns 1,194 shares of the medical instruments supplier’s stock valued at $297,000 after buying an additional 264 shares during the period. 85.32% of the stock is owned by institutional investors.
About C.R. Bard
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.